Legal

Conflict of Interest Policy

Last updated: June 7, 2026Aegis Peptide Analytics LLC

Core Commitment

“Aegis has zero financial relationships with any peptide manufacturer, supplier, distributor, or retailer — past, present, or future. Our only revenue is testing fees. This is not a preference. It is a structural constraint enforced by this policy.”

— Aegis Peptide Analytics founding charter, 2026

1. The Independence Principle

Aegis Peptide Analytics LLC was founded on the premise that a third-party testing laboratory is only as valuable as its independence. A result is only trustworthy if the entity producing that result has no financial stake in what the result is.

This policy formalizes our independence through binding structural commitments — not aspirational statements. Every employee, contractor, and officer of Aegis is bound by these requirements as a condition of their engagement with the company.

Our independence is the product we sell. Compromising it would destroy the only thing that makes our COAs worth having.

2. Scope

This policy applies to:

All full-time and part-time employees of Aegis Peptide Analytics LLC

All contractors, consultants, and temporary workers who perform services for Aegis

All officers and members of any advisory board

Any other individual acting on behalf of Aegis in a capacity that could influence testing or result reporting

This policy extends to immediate family members of covered individuals for the purposes of financial interest disclosure.

3. Prohibited Relationships and Interests

The following are absolutely prohibited for all covered individuals:

  • Equity ownership or investment interests in any peptide manufacturer, supplier, distributor, or retailer
  • Referral fee arrangements, affiliate commissions, or revenue-sharing agreements with supply-side entities
  • Receipt of free, discounted, or preferential products or services from any entity whose compounds may be submitted for testing
  • Employment, consulting, or advisory roles with any peptide supply company, concurrent with employment at Aegis
  • Acceptance of gifts, entertainment, or consideration of value from supply-side entities
  • Personal financial relationships that could influence testing priorities, methodology selection, or result reporting
  • Exclusive testing arrangements or preferred-partner agreements that create preferential treatment for any supplier's submissions

4. Disclosure Requirements

Covered individuals must proactively disclose to Aegis management:

  • Any prior employment at a peptide supplier or manufacturer within the previous five years
  • Ownership of more than 0.5% of any publicly-traded company in the peptide supply sector
  • Immediate family members employed by peptide supply entities
  • Any offer, solicitation, or approach by a supply-side entity that could constitute a conflict
  • Any financial interest in the outcome of a specific test result

Disclosures must be made within 5 business days of the covered individual becoming aware of the relevant circumstance. Disclosures are reviewed by management and documented in our conflict register. Failure to disclose is grounds for immediate termination.

5. Revenue Structure

Aegis Peptide Analytics' sole revenue source is testing fees paid by clients who submit samples for analysis. We do not:

Charge premium rates to suppliers seeking favorable results

Offer volume discounts conditioned on result outcomes

Accept payment contingent on a particular test result

Receive advertising, sponsorship, or endorsement revenue from any supply-chain entity

Our financial interest is in accurate results that maintain our reputation — not in any particular outcome for any particular compound.

6. Violations and Consequences

Any confirmed violation of this policy by any covered individual results in the following minimum consequences:

Immediate suspension from laboratory duties pending investigation

Termination of employment or engagement upon confirmed violation

Disclosure to clients whose tests may have been affected by the conflict

Public notice on our website that a violation occurred (without identifying details of the individual unless legally required)

We maintain this disclosure commitment because our clients deserve to know if our independence was ever compromised. Concealing a violation is treated as a violation in itself.

Suspected violations may be reported confidentially to management@aegispeptideanalytics.com.

7. Annual Review

This policy is reviewed annually. All covered individuals must certify their compliance with this policy on an annual basis and upon any change in their financial relationships or employment status.

We may retain an independent third party to audit our compliance with this policy. Audit findings are available to clients upon written request.

8. Questions and Reporting

Questions about this policy or reports of potential violations may be directed to:

**Aegis Peptide Analytics LLC — Compliance**

Email: compliance@aegispeptideanalytics.com

Clients who believe a conflict of interest may have affected their test results should contact us in writing. We will investigate and respond within 15 business days.